

## MOMOZ

### **For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only**

Abbreviated Prescribing information for MOMOZ [Mometasone Furoate Cream I.P.]

[Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

### **PHARMACOLOGICAL PROPERTIES:**

**MECHANISM OF ACTION:** Like other topical corticosteroids, Mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

**INDICATIONS:** It is topical corticosteroid - Used in steroid responsive dermatosis, eczema and atopic dermatitis.

**DOSAGE AND ADMINISTRATION:** Adults, including elderly patients and Children: A thin film of Mometasone Furoate Cream should be applied to the affected areas of skin once daily. Use of topical corticosteroids in children or on the face should be limited to the least amount compatible with an effective therapeutic regimen and duration of treatment should be no more than 5 days.

**CONTRAINDICATION:** Mometasone Furoate is contraindicated in facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal and genital pruritis, napkin eruptions, bacterial (e.g. impetigo, pyodermas), viral (e.g. herpes simplex, herpes zoster and chickenpox verrucae vulgares, condylomata acuminata, molluscum contagiosum), parasitical and fungal (e.g. candida or dermatophyte) infections, varicella, tuberculosis, syphilis or post vaccine reactions. Mometasone Furoate should not be used on wounds or on skin which is ulcerated. Mometasone Furoate should not be used in patients who are sensitive to Mometasone Furoate or to other corticosteroids or to any of the excipients.

**WARNINGS & PRECAUTIONS:** Systemic absorption of topical corticosteroids can produce reversible hypothalamic pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glycosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.

**DRUG INTERACTIONS:** None known

**ADVERSE REACTIONS:** Infection, furuncle, folliculitis, paraesthesia, burning sensation, dermatitis contact, skin hypopigmentation, hypertrichosis, skin striae, dermatitis acneiform, skin atrophy, pruritus, application site pain, application site reactions, and vision blurred.

**TORRENT**  
PHARMA

### **MARKETED BY:**

TORRENT PHARMACEUTICALS LTD.

**IN/MOMOZ 10, 30 gm/FEB-26/02/ABPI**

(Additional information is available on request)